Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added @ TPIV
Buyers market!
Added several more thousand shares at $7.50 as I suspect we will see more drops before Tuesday IMO. Best time to load the boat in awhile!
Investor 100
Added shares @ TPIV
Waited patiently to buy more on the dip and with this market dropping like a knife through butter picked up another few thousand shares at $7.65.
Like the company story, pending merge, and news throughout 18/19.
Investor 100
Sold @ IPCI
Small window for some profits today - out at $1.35 for a 22% gain!
GLTA
Investor 100
Bought shares @ IPCI
Took a gamble and bought almost at the bottom this morning...swing trade!
Investor 100
IPCI @ Stockcharts
No need to post the most recent chart as its a falling knife going through butter. I suspect with this stock price there has to be some news pending from IPCI management as the silence is deafening at this point.
Investor 100
Historical Perspective @ BIEL
This was one press release back in 2009 that raised my eyebrow and thought that this small company would one day be a big company given its early success. A lot of water under the bridge since this time when many including myself at times wanted to throw in the towel however a severe accident resulted in my purchase of the product with its healing success proved to me this was a stock to buy and own- thus here I am today since 2009 watching this company blossom into something much bigger than could have been envisioned back in the early days. Needless to say I own and hold my shares from early days as well as most recently on a dip..as I say no luck required just some patience!
FREDERICK, MD -- (Marketwire) -- 09/14/09 -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it has been selected as a runner up in the medical device category of the 2009 Wall Street Journal Innovation Awards unveiled in today's global editions and online. The award was given for the Company's wearable patch that uses pulsed electromagnetic energy to deliver drug-free pain relief for a variety of conditions.
Richard Staelin, Chairman of the Board of BioElectronics, said, "We are gratified that such a prestigious organization has validated the work of BioElectronics management to bring our innovative technology to market.
For a start-up of our size, it is exciting to be on a winners list that includes this year established technology leaders like Abbot Labs, HP, Qualcomm, National Semiconductor, Intel and NASA. The Wall Street Journal said that they received almost 500 nominations from around the world and selected only 36 winners." A complete file of this year's winners is available on the WSJ Online website or on http://www.healfasttherapy.com/wsjinnovationaward.
Andrew Whelan, BioElectronics CEO, will accept the award at The Wall Street Journal's 2009 Technology Innovation Awards ceremony on Oct. 13 at a dinner in Redwood City, Calif. featuring a keynote address by Marc Benioff, chairman and chief executive of Salesforce.com Inc. The ceremony will be held in conjunction with the Dow Jones VentureWire Technology Showcase.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com ) and the Allay(TM) family (www.AllayPatch.com) of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1062604
CVS Corporate Office -AnitiPatch -
Spoke with CVS corporate office for product distribution to confirm that our product is not available on shelves in all states. The CVS store in Ohio had product from a re-order only ( re-stock ).
If you have additional questions call CVS corporate at 401-765-1500.
Investor 100
614-855-5771
You are correct sir!
Called the store to confirm myself (DD) and they presently took shipment in last Thursday.
Not certain if this is a stand alone issue but given CVS this must be a new development not yet announced...very strange indeed.
https://www.cvs.com/store-locator/cvs-pharmacy-address/175+West+Main+Street-New+Albany-OH-43054/storeid=2677
Investor 100
Added Shares @ BIEL
The news on the ruling is a huge step forward and with that raises the bar for BIEL thus I added another 2M shares today.
Not a matter of luck but some patience for this to bust out!
Investor 100
IPCI @ Stockcharts
Without any doubt the stock chart is bullish with all three indicators RSI-MACD-MFI moving upward without any news as of yet- much speculation on the board but nothing set in stone. Volume over 1M shares on Friday is bullish.
There are more questions than answers that are expected to be delivered in the short term making this a speculative play.
I added a few shares this past week on pure speculation we get some positive news...hmmm
This week could perhaps clear the path for this companies future path!
GLTA
Investor 100
Added shares @ BIEL
Looks like a solid sell off with many exiting the gates however given I have been here since 2009 I added more shares to my loot at 2M shares- thank you for the dip and buying opportunity.
Not a matter of luck but some patience for this to bust out!
Investor 100
Plenty of Positive News @ CRMD
https://www.equities.com/news/4-emerging-growth-biotech-names-for-the-next-generation
RS: We are covering CorMedix Inc. (CRMD:NYSE.MKT), with a Buy rating and price target of $6.50/share. It is a particularly interesting name because it is developing a next-generation anti-infective solution called Neutrolin (taurolidine + citrate + heparin) to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis.
The company has the FDA's qualified infectious disease product (QIDP) designation, which was enabled by the Generating Antibiotic Incentives Now (GAIN) Act that was signed into law by President Obama in mid-2012. In our view, the CorMedix solution embodies a characteristic that is absolutely critical in the world of novel anti-infective development, and that is the ability to evade resistance by microorganisms and bacteria. Effectively, the company is using a non-antibiotic compound with the main active ingredient taurolidine, which has been widely assessed as active against various infectious organisms. Taurolidine is not like an antibiotic, against which resistance will always evolve. We think this platform positions CorMedix particularly well going forward.
The company is developing taurolidine, in combination with citrate and heparin, to address the issue of catheter colonization by bacteria to form biofilms. You're looking at CRBSIs in patients in the hospital with catheters threaded into their arms or threaded via a central line so they can be fed nutrients, be given a chemotherapy drug, or undergo hemodialysis. The catheter can, inevitably really, become colonized by all kinds of nasty bugs. Using the taurolidine catheter lock solution allows the company to effectively eliminate the bacterial colonization of these catheters.
TLSR: Is the compound bacteriostatic, or is it specifically targeting the formation of biofilms?
RS: Taurolidine has been documented to prevent biofilm formation, which sets it apart from typical antibiotics, which are not effective against biofilms. This puts CorMedix and Neutrolin in a privileged position among anti-infective agents, because Neutrolin can be used broadly without fear that resistance will occur and render it useless.
In addition, because Neutrolin is focused specifically on the CRBSI domain, there is a clear hospital- and dialysis center-based setting for the product. We're not talking about a mass-market product with hundreds of nationwide reps needed in a marketing effort.
We should see interim data from the first of two Phase 3 trials with Neutrolin later this year.
Obviously, if those data are positive, we believe CorMedix could obtain a very lucrative marketing partnership in the U.S., and would potentially be able to accelerate sales of Neutrolin in non-U.S. territories, particularly in Europe, where the compound is approved and marketed in certain countries.
TLSR: Your implied market cap is only about $230M, and I'm assuming that's a 12–18 month price target. As I look at Neutrolin, I'm thinking every intensive care unit (ICU) should be using it because nosocomial (hospital-acquired) infections are something institutions are focusing on. I'm also thinking that all the nephrology/dialysis centers should be using it. And there are other opportunities for taurolidine, such as prevention of urinary tract infections (UTIs) and associated catheter encrustation. Your implied market valuation seems very low considering the potential, and the fact that there is no other FDA-approved product like this on the market. Can you comment on that?
RS: I don't disagree with you. We have a relatively conservative viewpoint here, and the potential future upside may well be significantly greater than what we have projected.
We are, first of all, assuming market penetration only in the domain of CRBSIs—not in UTIs or any medical device or suture-related use of taurolidine. We are also not giving the company significant credit for the commercialization of Neutrolin outside of the U.S. We are only modeling sales in the areas of hemodialysis, ICU patients, patients on oncology drugs administered via intravenous drip, and patients receiving total parenteral nutrition.
In addition, we are assuming a relatively modest market cap compared to the current valuations of other single-product companies in the anti-infective domain—those developing antibiotics against which resistance will inevitably occur.
CRMD-Europe
http://cormedix-europe.com/home-349.html
Investor 100
CRMD @ Stockcharts
Berkeley Heights, NJ – July 25, 2018 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the interim analysis of the data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin®. Because the pre-specified level of statistical significance was reached and efficacy had been demonstrated, the DSMB recommended the study be terminated early. No safety concerns were reported by the DSMB based on the interim analysis. The company will submit the results of the interim analysis to the U.S. Food and Drug Administration for its review.
“We are thrilled to have received the DSMB’s recommendation that efficacy has been demonstrated. Once we have submitted the interim analysis results and DSMB’s recommendation to the FDA, we will begin the dialogue on the appropriate next steps,” said Khoso Baluch, Chief Executive Officer of CorMedix. “We have invested a significant amount of the Company’s resources over the last 2 ½ years in this study, and it is gratifying to have achieved this result based on the interim analysis. We believe Neutrolin has great potential to save lives of patients receiving hemodialysis therapy as a treatment for end stage renal disease and to lower overall healthcare costs due to reducing the risk of catheter-related blood stream infections (CRBSI).”
The primary endpoint of the Phase 3 LOCK-IT-100 study is reducing the risk of occurrence of CRBSI by Neutrolin relative to the active control of heparin. The secondary endpoints are catheter patency, which is defined as required use of tissue plasminogen activating factor (tPA) or removal of catheter due to dysfunction, and catheter removal for any reason.
http://www.cormedix.com/cormedix-inc-announces-positive-results-neutrolin-phase-3-lock-100-study-based-recommendation-independent-data-safety-monitoring-board/
The three indicators I watch RSI-MACD-MFI all look steady and perhaps will continue to reach higher PPS next week.
Investor 100
Good write up @ H.C Wainwright
Looking forward to more news in the weeks, months ahead!
We believe that submission of the interim data to the FDA could occur within the coming weeks. Given the significant unmet need in treating CRBSIs, which result in death for 20% or more of the patients who develop them, we feel that the FDA could prove amenable to considering fast-tracked submission of Neutrolin for review and accelerated approval for the product in the U.S. As such, therefore, we think there is a possibility now for Neutrolin to be filed before the end of this year and to be approved in 2019, vs. our original assumption that the drug would not enter the U.S. market prior to 2020. Furthermore, the news of the clear efficacy signal in the LOCK-IT-100 study could meaningfully accelerate ex-U.S. sales of the product. We reiterate our Buy rating and raise our price target to $3.00 from $2.00 per share on CRMD.”
http://www.analystratings.com/articles/h-c-wainwright-sticks-to-their-buy-rating-for-cormedix-inc/
Investor 100
Insiders & Institutions Holding shares
https://fintel.io/n/us/crmd
Investor 100
Nice jump of 5% in After Hour .54...looking good for next week!
Investor 100
Added shares @ BIEL
Nice day to add more shares on the dip...locked in the box for bigger gains in the weeks, months ahead.
Got the patch working on my back and shoulders...doctor stated no surgery!
No luck here just some patience!
Investor100
Bought in this afternoon...like the chances we go higher..
Investor 100
Looking at inside buys from officers bought in at .48.
Watching this one closely.
Investor 100
IPCI @ Stockcharts
Another look at IPCI with a quick look at major indicators with RSI and MACD showing strength movement upward with MFI curve downward but all in in all a chart that is shaping up. Any positive news would certainly created momentum that we all have been hoping to see! Holding shares.
Investor 100
Added Shares @ BIEL
Todays action with a solid dip provide me the opportunity to add another 2M shares to my war chest!
I know what I own since 2009 in shares, the patch has helped my entire family over many years, and think we see more news in the weeks, months and years ahead!
No luck required just some patience.
Investor 100
Adding Shares @ BIEL
Took advantage of this dip with another 1M shares to my war chest!
Looking forward to next week May 29th FDA meeting with updates and much more news throughout 2018 /2019.
No luck needed just some patience
Investor 100
Well stated sir and sorry for your loss.
I cannot image the pain and agony you experienced so thanks for sharing.
Investor 100
Thanks for the solid summary of events.
Lots has changed since I joined in 2009 and much is coming in 2018/2019!
No luck needed just patience.
Investor 100
Agree, the big difference is now we have a product that the FDA recognizes and has approved along with a VP Sales whose business network is helping brand this product with the PPS ready to follow.
No luck needed just some patience.
Investor 100
Nice find and update as we continue to show tremendous progress.
No luck needed just some patience.
Investor 100
Historical Perspective @ BIEL
For a small start-up company back in 2009 this achievement among the heavy weights is d*m impressive to say the least!
BioElectronics Wins Wall Street Journal 2009 Innovation Award
FREDERICK, MD -- (Marketwire) -- 09/14/09 -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it has been selected as a runner up in the medical device category of the 2009 Wall Street Journal Innovation Awards unveiled in today's global editions and online. The award was given for the Company's wearable patch that uses pulsed electromagnetic energy to deliver drug-free pain relief for a variety of conditions.
Richard Staelin, Chairman of the Board of BioElectronics, said, "We are gratified that such a prestigious organization has validated the work of BioElectronics management to bring our innovative technology to market.
For a start-up of our size, it is exciting to be on a winners list that includes this year established technology leaders like Abbot Labs, HP, Qualcomm, National Semiconductor, Intel and NASA. The Wall Street Journal said that they received almost 500 nominations from around the world and selected only 36 winners." A complete file of this year's winners is available on the WSJ Online website or on www.healfasttherapy.com/wsjinnovationaward.
Andrew Whelan, BioElectronics CEO, will accept the award at The Wall Street Journal's 2009 Technology Innovation Awards ceremony on Oct. 13 at a dinner in Redwood City, Calif. featuring a keynote address by Marc Benioff, chairman and chief executive of Salesforce.com Inc. The ceremony will be held in conjunction with the Dow Jones VentureWire Technology Showcase.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com ) and the Allay(TM) family (www.AllayPatch.com) of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1062604
No luck needed just some patience!
Historical Perspective @ Biel
No question BIEL was a popular company back in the days of 2009 as many folks could not get enough calls or join the CC. That excitement has continued almost 10 years later...good things are happening at BIEL.
BioElectronics Board Comments on Recent Trading Activity
Company to Execute Plan to Move to OTC Market -- Provides Update on Corporate Activities
FREDERICK, MD--(Marketwire - 08/26/09) - BioElectronics Corp. (Pinksheets:BIEL - News), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today provided its investors commentary on recent trading activity, its intention to move to the over-the-counter board and made comments relative to corporate activities. The following comments were approved by the Board of Directors of BioElectronics.
For the past several months, Pink OTC Markets Inc., a company that provides the leading interdealer electronic quotation and trading system in the over-the-counter securities market, has blocked quotes for our shares from its website until adequate current information is made available. Additionally, this organization has claimed BioElectronics has engaged in questionable promotion of its stock. Several weeks ago we filed some of the information that is being requested, including income statements, balance sheets and statements of cash flows for the period ending June 2009. These financial statements outlined our recent obtainment of profitability and positive cash flow. We are currently diligently working to provide the additional requested information.
Shareholder interest in BioElectronics is highly significant, which has resulted in a torrent of telephone calls and e-mails into the Company from investors requesting information, overwhelming our limited staff. More than 2,250 investors dialed into our last conference call with several hundred others being unable to gain access due to the capacity of the conference bridge being reached. Each day we receive dozens, and often hundreds, of phone calls and e-mails requesting information. Simply put -- investors are extremely enthusiastic, as are we, relative to our revolutionary, drug-free therapeutic devices and our future. Our shareholders have clearly stated their desire for us to maintain a continuing flow of information relative to our opportunities and activities. The issuance of press releases is the easiest way for us to communicate the considerable amount of information desired by our shareholder base.
According to our conversations with officials from Pink OTC Markets, the number of press releases we have issued, in their opinion, constitutes questionable promotion with the security being promoted to the public, but adequate current information about the issuer is not being made available to the public. While we understand Pink Sheets' need to monitor activities, we vigorously object to this organization's characterization that we have been engaged in questionable promotion of our stock. However, we plan to work closely with the organization to provide the information they are requesting.
The management team of BioElectronics is also currently working on a plan to move the listing of our stock to the Over-The-Counter (OTC) or another stock exchange and we are hoping to discuss these details with our shareholders over the coming weeks.
Additionally, we are currently in the process of organizing additional clinical trials. For example, we recently announced a study to compare the use of ActiPatch? Therapy for muscle pain and soreness to industry leading acetaminophen brand, Tylenol?. Patient recruitment for the study is significantly ahead of schedule and our primary investigator on the study is expecting a quick conclusion with data available over the next 60 days. While we do not believe we will need the data from these additional trials to support our currently planned FDA filings, these additional studies will further enhance our position in both the clinical setting and consumer markets.
Our priorities remain the same. We plan to continue to move toward conclusion of our clinical trials, data from which will be used to support our upcoming applications with the U.S. Government's Food and Drug Administration (FDA). Several of these trials are now coming to a close and over the coming weeks we plan to submit multiple applications to the FDA. The data we will present to the FDA will be compelling. Considering our technology is already cleared for use for one indication by the FDA, we believe our odds of clearance for additional indications are very high.
We are also continuing our aggressive international expansion with Company personnel this week visiting the Republic of Korea, India and Italy to work directly with our distributors in-country. Our recent guarantee by the U.S. Government's Export-Import Bank will meaningfully assist our international expansion efforts.
We believe our revolutionary ActiPatch and Allay(TM) products belong on the U.S. retail store shelf alongside other major pain relief and feminine product brands and it is our overall goal to ensure such placement occurs. We continue to believe the future for our Company is very bright. Our intent is to build a worldwide brand for drug-free pain relief and we believe we are making significant strides toward this aim. The coming few weeks and months will be very exciting for our management team, employees and our shareholders.
http://finance.yahoo.com/news/BioElectronics-Board-Comments-iw-3484595295.html?x=0&.v=1
No luck needed just some patience.
Investor 100
Adding shares @ Biel
Acquired another 1M shares of BIEL
I have been using the product for years and given the results I shared the product with my doctor who then ordered it for his family! I have been off med's for years with shoulder and neck issues.
This company has come a long way since I joined in 2009!
No luck needed just some patience.
Investor 100
Adding shares @ BIEL
Like this dip opportunity to add more shares to my war chest!
Family uses the product and it works ( shoulder and neck ).
Looking at the bigger picture in 12-24 months - been around since 2009 !
No luck needed just some patience
Investor 100
Added shares @ BIEL
Thank you for the dip providing me the opportunity to add another 1M shares to my war chest! This is a company whose product works for me and my family and believe since the time I joined in 2009 we have come a long way and will continue to build this business - one step at a time-!
No luck needed just some patience.
Investor 100
Added shares @ BIEL
Took advantage of todays weak hands an added another 1M shares to my war chest!
Another Historical Review on my notes back in 2009 from a conference call are fun to read knowing how far we have come and where we are going...like a fine wine it takes some patience!
Trial Presentation – Dr. David Genecov, M.D., FACS-FAAP – Leading surgeon especially in Wound Care was a lead investigatore on Evaluating the ActiPatch on Plantar Fasiitis (Heel Pain). A condition that is difficult for people to walk. The trial evaluated the Actipatch at night with Placebo vs. active prdt. Treated Patients for 7 days…..looked at 55 patients….another 20 Patient will be evaluated soon. Trial has gone thru IRB. Very Solid Trial. Trending shows that on Day 4, there is a decrease of pain with less medication. Typically using over the counter medication for pain. The Dr. had a Personal story –Tylenol….Issues with kidneys. His father used Tylenol for back pain…..ended up with Kidney failure due to the drugs. He believes that this product would had prevented this side affect. He will have a publication for the trial by the end of the year. He has had a few physician colleagues interested in his trial and patient’s response. The company will have access to the data for FDA filing very soon.
Allay Patch User. Dr. Aria (Mispelled?) MD – LA She shared her personal experience on the Allay Patch. She had several issues with her conditions only able to use Tylenol but then used Midol which helped but led to chronic gastritis. She started using the actipatch about two months ago. She says PMS basically stops her from doing anything for about 2 or 3 days a month. She has to plan her life around her periods that are so painful. Can’t travel and she needs to stay home. So glad she found it. On the first day of using the actipatch, she noticed benefit in a couple of hours. Still had some pain, but much better. By the second day, the pain was almost completely gone. By the third day, the pain was gone. On a scale of 1-10, PMS pain without patch is a 10. After 4-5 hours of use, pain is a 5 on the first day. By second day, pain is a 0. (Joel mentioned on a Scale is 1-10.)
International Distribution. – Update – Expanding Western Europe. They will be distributing to Germany and Spain. Biggest Market is Germany in Europe. Making progress in Italy and Canada. Plan to ramp up distribution in Europe and Asia markets.
Status of FDA filings – Will have Actipatch. Have a demand for clinical studies. A lot investigators coming to the company to participate. Pushing hard for a clinical study on cesarian section Blindness study. Hernia study. Company will be slowing down the amt of trials since they want to focus on what is on the table today.. June 15 for Allay Period Patch. Planning to hear from FDA very soon. They will file for general surgery indication. Doing this will leap frog a FDA filings for a Global Muscular Skeleton Back pain. Pushing Company wants to put product on Walgreens etc. Dr. Genecov, M.D., FACS-FAAP trial is the key to these top indications.
Market Stats – Carrie Synder – Independent Consultant for BIEL– Comprehensive study published at the end of THIS week. Market research study. Will file on BIEL. The Study will show thatthese products could potential reach into the BILLIONS of dollars if the penetration is large but will be conservative on the potential for today’s discussion. Mentioned the Global Pain Surgeryarea could have 4 -5 % growth with 3 -4 billion market place. This represents 37% of pain relief market She shared 4 areas of focus 1. Cesarean Market. Mothers don’t No drugs due to concerns about Nursing 1.2 mill C sections performed in the US.. 20 % penetration equals $13.4 millions 2. Cosmetic Market. Breast Augmentation – Small market to reconstructive surgery. 6.6 million procedures representing about 20 % of the market . Equals about$ 66 million in US only. 3.Menstrual Pain Relief – Million of woman. Huge market 50 mill women 10 mill users 5 % Users = Market share potential is $80 million per year. 4. Lower back Pain – Biggest market to Muscular Skeletal - Last year had 16 mill patients which at 10% market share equal $65 million potential annual. Just summary for US = 225 million per year….for US. IF you market for world with US accts could equal 500 million ann. revs. Worldwide: $1-$2 billion/year. These are conservative. Huge returns. She's giving very conservative estimates on markets. This is for United States only. There is very little competition out there. Especially given that BIEL has patent to portable PEMF therapy.
Tylenol Press and FDA Panel review – July 3rd Panel – Brought in a panel of scientist and docs to review this with FDA. Number 1 cause is liver failure. Suggested to pull off Extra Strength Tylenol off the market and decrease – Had score of 39 before panel to 16 acceptance score a few days after the panel recommendations. Market is trying to position against Tylenol. Drug free solution. Patent is key to their products. Have applied for a second patent for large scope of indications.
Financials – 80% recent Q’s to Company are about financial picture. Now $910K covertures Debt to $50,000 convertible is down below 50K. Convertibility Debt Free. Down size has been dilution. Downside has been dilution and now they say they are looking in rearview window with dilution. Company is not concerned with liquidity. Won’t raise significant cash and think stock is still undervalued. Improvements in gross margins similar to any pharmaceutical company and as volumes up cost per unit will go down.
Company has been keeping expenses down as well Cost of capital has dropped. Gross Margin on the prdts. Improvement to manufacturing process. As the volumes move up….the Gross Margins will drop. Company has done a great job on controlling cost. Breaking even now. Export/Import Bank – have a guarantee by US government to help BIEL on exports. Cost of Capital is very low. Nice profits moving forward. Hire two brand managers to help BIEL markets.
Top priority is the clinical studies. Many of the trials are finishing. Dr. Genecov, M.D., FACS-FAAP Data is pivotal and a key for the indication on back pain. Large market. Further looking to Muscular Skeleton indication. They top priority is to “Rewrite the thought of How to Manage Pain” .
Investor 100
Historical Perspective @ BIEL (2009)
There was much to be proud back in 2009 with this distinguished award given to Biel on product innovation by Wall Street Journal. In great company if you look at the guest speaker was ( Mark Benioff of Salesforce) whose company is impressive on all levels.
I have been here since 2009 - I know what I own, use the product for my back and shoulder successfully, and believe that better days, weeks, months and years ahead for this company. Own it not trade it!
BioElectronics Wins Wall Street Journal 2009 Innovation Award
FREDERICK, MD -- (Marketwire) -- 09/14/09 -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it has been selected as a runner up in the medical device category of the 2009 Wall Street Journal Innovation Awards unveiled in today's global editions and online. The award was given for the Company's wearable patch that uses pulsed electromagnetic energy to deliver drug-free pain relief for a variety of conditions.
Richard Staelin, Chairman of the Board of BioElectronics, said, "We are gratified that such a prestigious organization has validated the work of BioElectronics management to bring our innovative technology to market.
For a start-up of our size, it is exciting to be on a winners list that includes this year established technology leaders like Abbot Labs, HP, Qualcomm, National Semiconductor, Intel and NASA. The Wall Street Journal said that they received almost 500 nominations from around the world and selected only 36 winners." A complete file of this year's winners is available on the WSJ Online website or on http://www.healfasttherapy.com/wsjinnovationaward.
Andrew Whelan, BioElectronics CEO, will accept the award at The Wall Street Journal's 2009 Technology Innovation Awards ceremony on Oct. 13 at a dinner in Redwood City, Calif. featuring a keynote address by Marc Benioff, chairman and chief executive of Salesforce.com Inc. The ceremony will be held in conjunction with the Dow Jones VentureWire Technology Showcase.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com ) and the Allay(TM) family (www.AllayPatch.com) of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1062604
Without a doubt this company got a lot of press and a big award however it just did not meet the challenges that are required to get it successfully approved with the FDA whom at that time were very skeptical in this category as well as going against big pharma that was advocating pills as the best solution at that time. The bottom line is the product and science was there but the folks at the FDA and big pharma wanted nothing to do with it...that tide has turned the page with todays pain killer pills!
https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf
This category is legitimate and the mood at the FDA is much different than it was back in 2009 thus it is impressive that Andy has endured many hurdles to get to where we are today.
BioElectronics Announces Tylenol(R) Comparative Study
Clinical Investigators to Compare ActiPatch(R) Therapy to Tylenol(R) for Treatment of Muscle Pain and Soreness
FREDERICK, MD--(Marketwire - 08/24/09) - BioElectronics Corp. (Pinksheets:BIEL - News), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it will sponsor a clinical study comparing the effects of ActiPatch? Therapy to Tylenol? for the treatment of muscle pain and soreness. The study will be conducted in two locations utilizing three groups of subjects, 1) a control group, 2) a group that will utilize ActiPatch Therapy, and 3) a group that will be given acetaminophen in the form of Tylenol?. Patient recruitment has already begun and preliminary data is expected within 60 days.
"As the debate over Tylenol? and other over the counter pain remedies, such as ibuprofen continues, the American public is becoming increasingly leery about taking these medications. We believe drug-free ActiPatch and the Allay Period Relief Patch are safe and highly effective alternatives to these drugs and this study is specifically designed to evaluate our beliefs," commented Andrew Whelan, CEO of BioElectronics, Corp. "We expect increased public attention on the potential dangers of over-the-counter pain medication as the public comment period with the FDA closes on September 30, 2009 and as expected FDA action takes place shortly thereafter. We welcome the opportunity to compare the efficacy of our drug-free technology directly to that of Tylenol?. Considering the market for acetaminophen is valued at $2.6 billion per year within the United States alone, we believe our opportunities relative to this area are significant."
On June 29 and June 30, 2009 the U.S. Government's Food and Drug Administration (FDA) convened a public advisory committee meeting regarding acetaminophen use in both over-the-counter and prescription products, the potential for liver injury, and potential interventions to reduce the incidence of liver injury. Data from both FDA's Adverse Event Reporting System (AERS) and the Acute Liver Failure Study Group (ALFSG) showed that the median daily dose of acetaminophen related to liver injury was 5.0 to 7.5 grams per day, very near the current maximum daily dose of 4.0 grams per day. FDA has stated that taking just a small amount of acetaminophen over the recommended daily dose may lead to liver injury -- even death. For many people, particularly those who consume much alcohol or have underlying liver disease, even 4.0 grams per day may cause liver injury.
The advisory panel recommended decreasing the maximum daily dose to 2.6 grams from 4.0 grams, and also voted to make the 1,000 mg dosage of acetaminophen available only by prescription. The FDA has said that U.S. consumers spent approximate $2.6 billion yearly on 28 billion doses of products that contain acetaminophen. As of April 29, 2010 the FDA will require new labeling to inform consumers about the risk of liver injury when using acetaminophen (such as Tylenol?) and the risk of stomach bleeding when using NonSteroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen (such as Advil? and Motrin?) and naproxen (such as Aleve?).
Historical Perspective @ BIEL (2009)
There was much to be proud back in 2009 with this distinguished award given to Biel on product innovation by Wall Street Journal. In great company if you look at the guest speaker ( Mark Benioff of Salesforce)
I have been here since 2009 - I know what I own, use the product for my back and shoulder successfully, and believe that better days, weeks, months and years ahead for this company. Own it not trade it!
BioElectronics Wins Wall Street Journal 2009 Innovation Award
FREDERICK, MD -- (Marketwire) -- 09/14/09 -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it has been selected as a runner up in the medical device category of the 2009 Wall Street Journal Innovation Awards unveiled in today's global editions and online. The award was given for the Company's wearable patch that uses pulsed electromagnetic energy to deliver drug-free pain relief for a variety of conditions.
Richard Staelin, Chairman of the Board of BioElectronics, said, "We are gratified that such a prestigious organization has validated the work of BioElectronics management to bring our innovative technology to market.
For a start-up of our size, it is exciting to be on a winners list that includes this year established technology leaders like Abbot Labs, HP, Qualcomm, National Semiconductor, Intel and NASA. The Wall Street Journal said that they received almost 500 nominations from around the world and selected only 36 winners." A complete file of this year's winners is available on the WSJ Online website or on http://www.healfasttherapy.com/wsjinnovationaward.
Andrew Whelan, BioElectronics CEO, will accept the award at The Wall Street Journal's 2009 Technology Innovation Awards ceremony on Oct. 13 at a dinner in Redwood City, Calif. featuring a keynote address by Marc Benioff, chairman and chief executive of Salesforce.com Inc. The ceremony will be held in conjunction with the Dow Jones VentureWire Technology Showcase.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com ) and the Allay(TM) family (www.AllayPatch.com) of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1062604
That is based upon a company back in 2009 whose product was in trials at that time.
Stock Valuation -- There are currently approximately 720 million outstanding shares, which represent a total market capitalization of approximately $7.2 million. Even though the price of BioElectronics Corp. shares has risen substantially over the past few weeks, the management team believes the stock is still significantly undervalued.
FDA Filings -- Early this week BioElectronics filed two applications with the FDA. The first of these was for 510(k) marketing clearance for its Allay Menstrual Pain Relief Patch product seeking OTC marketing clearance and an indication for pain reduction associated with dysmenorrhea (period pain and cramps). The second FDA filing was for a reclassification of the Company's technologies from Class III to Class II.
Biel is a much different company today as we all know from past PR's to the most recent meeting with the FDA and another on May 29th thus I know what I own and plan to ride this out to the end!
Investor 100